Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04586231
Title A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

clear cell renal cell carcinoma

Therapies

Belzutifan + Lenvatinib

Cabozantinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUT


No variant requirements are available.